stockrowEnliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −8.34%
Quarter to June 2026, against a year earlier
Follow ELVN
Alert me
Enliven Therapeutics, Inc. (ELVN) Free cash flow
Enliven Therapeutics, Inc.'s free cash flow for fiscal 2025 was −$70.2M, compared with −$73.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$67.0M. Over the past ten years it has ranged from −$73.2M (fiscal 2024) to −$8.8M (fiscal 2018); the current reading is higher than 22% of that period. Enliven Therapeutics, Inc. ranks 385th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$70.2M | — |
| FY2024 | −$73.2M | — |
| FY2023 | −$61.4M | — |
| FY2022 | −$32.7M | — |
| FY2021 | −$46.8M | — |
| FY2020 | −$37.4M | — |
| FY2019 | −$22.0M | — |
| FY2018 | −$8.8M | — |
| FY2017 | −$8.8M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$18.6M | — |
| Mar 2026 | −$19.3M | — |
| Dec 2025 | −$15.6M | — |
| Sep 2025 | −$13.3M | — |
| 26 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $82.0M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $32.4M |
| TLX Telix Pharmaceuticals Limited compare | −$4.4M |
| ELVN Enliven Therapeutics, Inc. | −$67.0M |
| CELC Celcuity, Inc. compare | −$192.3M |
| VRDN Viridian Therapeutics, Inc. compare | −$343.4M |
| DNLI Denali Therapeutics Inc. compare | −$450.0M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$480.4M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)